Skip to main content
S 150 118th Congress Senate Health Administrative remedies Civil actions and liability Competition and antitrust Consumer affairs Drug safety, medical device, and laboratory regulation Federal Trade Commission (FTC) Health care costs and insurance Inflation and prices Intellectual property Judicial review and appeals Manufacturing Prescription drugs

Affordable Prescriptions for Patients Act of 2023

Introduced: January 30, 2023 Introduced by: Cornyn, John Republican · Texas See on congress.gov
 Everywhere this bill has been 11 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 15, 2024
Held at the desk.
Jul 15, 2024
Received in the House.
Jul 12, 2024
Message on Senate action sent to the House.
Jul 11, 2024
Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S4537-4538)
Jul 11, 2024
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.
Jul 11, 2024
Measure laid before Senate by unanimous consent. (consideration: CR S4537-4538)
Mar 1, 2023
Placed on Senate Legislative Calendar under General Orders. Calendar No. 22.
Mar 1, 2023
Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.
Feb 9, 2023
Committee on the Judiciary. Ordered to be reported without amendment favorably.
Jan 30, 2023
Read twice and referred to the Committee on the Judiciary.
Jan 30, 2023
Introduced in Senate
 Plain-English summary Congressional Research Service

Affordable Prescriptions for Patients Act of 2023

This bill limits in certain instances the number of patents that a reference biological product manufacturer can assert in a patent infringement lawsuit against a company seeking to sell a biosimilar version.

Specifically, if the biosimilar manufacturer completes certain actions as part of an abbreviated pathway to get market approval, the bill limits, subject to exceptions and waivers, the number of certain types of patents that the reference product manufacturer may assert, such as patents filed more than four years after the reference product received market approval.

 

 

What's happening now July 15, 2024

Held at the desk.

 Committees of jurisdiction 1